Levonorgestrel (oral): Difference between revisions

	WikiDoc Resources for Levonorgestrel (oral)
Articles
Most recent articles on Levonorgestrel (oral) Most cited articles on Levonorgestrel (oral) Review articles on Levonorgestrel (oral) Articles on Levonorgestrel (oral) in N Eng J Med, Lancet, BMJ
Media
Powerpoint slides on Levonorgestrel (oral) Images of Levonorgestrel (oral) Photos of Levonorgestrel (oral) Podcasts & MP3s on Levonorgestrel (oral) Videos on Levonorgestrel (oral)
Evidence Based Medicine
Cochrane Collaboration on Levonorgestrel (oral) Bandolier on Levonorgestrel (oral) TRIP on Levonorgestrel (oral)
Clinical Trials
Ongoing Trials on Levonorgestrel (oral) at Clinical Trials.gov Trial results on Levonorgestrel (oral) Clinical Trials on Levonorgestrel (oral) at Google
Guidelines / Policies / Govt
US National Guidelines Clearinghouse on Levonorgestrel (oral) NICE Guidance on Levonorgestrel (oral) NHS PRODIGY Guidance FDA on Levonorgestrel (oral) CDC on Levonorgestrel (oral)
Books
Books on Levonorgestrel (oral)
News
Levonorgestrel (oral) in the news Be alerted to news on Levonorgestrel (oral) News trends on Levonorgestrel (oral)
Commentary
Blogs on Levonorgestrel (oral)
Definitions
Definitions of Levonorgestrel (oral)
Patient Resources / Community
Patient resources on Levonorgestrel (oral) Discussion groups on Levonorgestrel (oral) Patient Handouts on Levonorgestrel (oral) Directions to Hospitals Treating Levonorgestrel (oral) Risk calculators and risk factors for Levonorgestrel (oral)
Healthcare Provider Resources
Symptoms of Levonorgestrel (oral) Causes & Risk Factors for Levonorgestrel (oral) Diagnostic studies for Levonorgestrel (oral) Treatment of Levonorgestrel (oral)
Continuing Medical Education (CME)
CME Programs on Levonorgestrel (oral)
International
Levonorgestrel (oral) en Espanol Levonorgestrel (oral) en Francais
Business
Levonorgestrel (oral) in the Marketplace Patents on Levonorgestrel (oral)
Experimental / Informatics
List of terms related to Levonorgestrel (oral)

Levonorgestrel (oral)
Clinical data
Pregnancy; category	X;
Routes of; administration	Implant; insert (extended-release); oral
ATC code	G03AC03 (WHO) ;
Pharmacokinetic data
Bioavailability	~100%
Protein binding	55%
Metabolism	Hepatic
Elimination half-life	36 ± 13 hours
Excretion	Renal: 45%; Fecal:32%
Identifiers
	IUPAC name 13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one;
CAS Number	797-63-7;
PubChem CID	13109;
DrugBank	APRD00754;
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C21H28O2
Molar mass	312.446 g/mol

Levonorgestrel (oral)
	Adult Indications & Dosage
	Pediatric Indications & Dosage
	Contraindications
	Warnings & Precautions
	Adverse Reactions
	Drug Interactions
	Use in Specific Populations
	Administration & Monitoring
	Overdosage
	Pharmacology
	Clinical Studies
	How Supplied
	Images
	Patient Counseling Information
	Precautions with Alcohol
	Brand Names
	Look-Alike Names

← Older edit Newer edit →

VisualWikitext

Revision as of 15:21, 12 January 2015

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Alberto Plate [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Levonorgestrel (oral) is an emergency contraceptive that is FDA approved for the prophylaxis of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse. Common adverse reactions include menstrual bleeding, nausea, lower abdominal pain, fatigue, headache, and dizziness.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Emergency Contraceptive

Dosage: Taken orally as soon as possible within 72 hours after unprotected intercourse or a known or suspected contraceptive failure. Efficacy is better if the tablet is taken as soon as possible after unprotected intercourse. Each round tablet containing 1.5 mg of levonorgestrel.

Menorrhagia

Dosage: Disposed as an IUD which releases 20 micrograms/day.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Levonorgestrel in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Levonorgestrel in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Levonorgestrel (oral) FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Levonorgestrel in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Levonorgestrel in pediatric patients.

Contraindications

Contraindicated for use in the case of known or suspected pregnancy.

Warnings

Ectopic Pregnancy

Ectopic pregnancies account for approximately 2% of all reported pregnancies. Up to 10% of pregnancies reported in clinical studies of routine use of progestin-only contraceptives are ectopic.

A history of ectopic pregnancy is not a contraindication to use of this emergency contraceptive method. Healthcare providers, however, should consider the possibility of an ectopic pregnancy in women who become pregnant or complain of lower abdominal pain after taking Levonorgestrel. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Next Choice One DoseTM.

Existing Pregnancy

Levonorgestrel is not effective in terminating an existing pregnancy.

Effect on Menses

Some women may experience spotting a few days after taking Levonorgestrel. Menstrual bleeding patterns are often irregular among women using progestin-only oral contraceptives and women using levonorgestrel for postcoital and emergency contraception.

If there is a delay in the onset of expected menses beyond 1 week, consider the possibility of pregnancy.

STI/HIV

Levonorgestrel does not protect against HIV infection (AIDS) or other sexually transmitted infections (STIs).

Physical Examination and Follow-up

A physical examination is not required prior to prescribing Next Choice One DoseTM. A follow-up physical or pelvic examination is recommended if there is any doubt concerning the general health or pregnancy status of any woman after taking Levonorgestrel.

Fertility Following Discontinuation

A rapid return of fertility is likely following treatment with Levonorgestrel for emergency contraception; therefore, routine contraception should be continued or initiated as soon as possible following use of Next Choice One DoseTM to ensure ongoing prevention of pregnancy.

Presence of FD&C Yellow

Levonorgestrel contains FD&C Yellow #6 as a color additive.

Adverse Reactions

Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Levonorgestrel tablet was studied in a randomized, double-blinded multicenter clinical trial. In this study, all women who had received at least one dose of study medication were included in the safety analysis: 1,379 women in the levonorgestrel tablet group (1 dose of 1.5 mg levonorgestrel), and 1,377 women in the levonorgestrel tablets group (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). The mean age of women given levonorgestrel tablet was 27 years. The racial demographic of those enrolled was 54% Chinese, 12% Other Asian or Black, and 34% were Caucasian in each treatment group. 1.6% of women in the levonorgestrel tablet group and 1.4% in levonorgestrel tablets group were lost to follow-up.

The most common adverse events (>10%) in the clinical trial for women receiving levonorgestrel tablet included heavier menstrual bleeding (30.9%), nausea (13.7%), lower abdominal pain (13.3%), fatigue (13.3%), and headache (10.3%). Table 1 lists those adverse events that were reported in > 4% of levonorgestrel tablet users.

Postmarketing Experience

The following adverse reactions have been identified during post-approval use of levonorgestrel tablets (2 doses of 0.75 mg levonorgestrel taken 12 hours apart). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Gastrointestinal Disorders

General Disorders and Administration Site Conditions

Fatigue

Nervous System Disorders

Reproductive System and Breast Disorders

Drug Interactions

Drugs or herbal products that induce enzymes, including CYP3A4, that metabolize progestins may decrease the plasma concentrations of progestins, and may decrease the effectiveness of progestin-only pills. Some drugs or herbal products that may decrease the effectiveness of progestin-only pills include:

Significant changes (increase or decrease) in the plasma levels of the progestin have been noted in some cases of coadministration with HIV protease inhibitors or with non-nucleoside reverse transcriptase inhibitors.

Consult the labeling of all concurrently used drugs to obtain further information about interactions with progestin-only pills or the potential for enzyme alterations.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): X Many studies have found no harmful effects on fetal development associated with long-term use of contraceptive doses of oral progestins. The few studies of infant growth and development that have been conducted with progestin-only pills have not demonstrated significant adverse effects.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Levonorgestrel (oral) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Levonorgestrel (oral) during labor and delivery.

Nursing Mothers

In general, no adverse effects of progestin-only pills have been found on breastfeeding performance or on the health, growth, or development of the infant. However, isolated post-marketing cases of decreased milk production have been reported. Small amounts of progestins pass into the breast milk of nursing mothers taking progestin-only pills for long-term contraception, resulting in detectable steroid levels in infant plasma.

Pediatric Use

Safety and efficacy of progestin-only pills for long-term contraception have been established in women of reproductive age. Safety and efficacy are expected to be the same for postpubertal adolescents less than 17 years and for users 17 years and older. Use of Next Choice One DoseTM emergency contraception before menarche is not indicated.

Geriatic Use

This product is not intended for use in postmenopausal women.

Gender

There is no FDA guidance on the use of Levonorgestrel (oral) with respect to specific gender populations.

Race

No formal studies have evaluated the effect of race. However, clinical trials demonstrated a higher pregnancy rate in Chinese women with both levonorgestrel tablets (2 doses of 0.75 mg levonorgestrel taken 12 hours apart) and the Yuzpe regimen (another form of emergency contraception). There was a non-statistically significant increased rate of pregnancy among Chinese women in the levonorgestrel tablet trial. The reason for this apparent increase in the pregnancy rate with emergency contraceptives in Chinese women is unknown.

Renal Impairment

No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablet.

Hepatic Impairment

No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablet.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Levonorgestrel (oral) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Levonorgestrel (oral) in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Levonorgestrel (oral) Administration in the drug label.

Monitoring

There is limited information regarding Levonorgestrel (oral) Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Levonorgestrel (oral) and IV administrations.

Overdosage

There are no data on overdosage of levonorgestrel tablet, although the common adverse event of nausea and associated vomiting may be anticipated.

Pharmacology


Template:Px
Levonorgestrel (oral)
Systematic (IUPAC) name
(8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[a]phenanthren-3-one
Identifiers
CAS number	797-63-7
ATC code	G03AC03 G03AD01 (WHO)
PubChem	13109
DrugBank	DB00367
Chemical data
Formula	Template:OrganicBox atom Template:OrganicBox atom Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox atom Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox Template:OrganicBox
Mol. mass	312.446 g/mol
SMILES	eMolecules & PubChem
Pharmacokinetic data
Bioavailability	~100%
Protein binding	55%
Metabolism	Hepatic via CYP3A4^{[citation needed]}
Half life	36 ± 13 hours
Excretion	Renal: 45%; Fecal:32%
Therapeutic considerations
Pregnancy cat.	X
Legal status	Rx-OTC
Routes	Implant; insert (extended-release); oral

Mechanism of Action

Emergency contraceptive pills are not effective if a woman is already pregnant. Levonorgestrel is believed to act as an emergency contraceptive principally by preventing ovulation or fertilization (by altering tubal transport of sperm and/or ova). In addition, it may inhibit implantation (by altering the endometrium). It is not effective once the process of implantation has begun.

Structure

The inactive ingredients present are colloidal silicon dioxide, corn starch, FD&C Yellow #6, lactose monohydrate, magnesium stearate, povidone.

Levonorgestrel has a molecular weight of 312.45, and the following structural and molecular formulas:

Pharmacodynamics

There is limited information regarding Levonorgestrel (oral) Pharmacodynamics in the drug label.

Pharmacokinetics

Absorption

Following a single dose administration of levonorgestrel 1.5 mg in 30 women under fasting conditions, maximum plasma concentrations of levonorgestrel of 19.1 ng/mL were reached at 1.7 hours.

Nonclinical Toxicology

There is limited information regarding Levonorgestrel (oral) Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Levonorgestrel (oral) Clinical Studies in the drug label.

How Supplied

There is limited information regarding Levonorgestrel (oral) How Supplied in the drug label.

Storage

There is limited information regarding Levonorgestrel (oral) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Levonorgestrel (oral) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Levonorgestrel (oral) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Levonorgestrel (oral) Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Levonorgestrel interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Levonorgestrel (oral) Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Levonorgestrel (oral) Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

Levonorgestrel (or l-norgestrel or D-norgestrel) is a synthetic progestogen used as an active ingredient in some hormonal contraceptives.

Chemistry

Chemically, it is a hormonally active levorotatory enantiomer of the racemic mixture norgestrel. It is a gonane progestin derived from 19-nortestosterone.^[1]

Its in vitro relative binding affinities at human steroid hormone receptors are: 323% that of progesterone at the progesterone receptor, 58% that of testosterone at the androgen receptor, 17% that of aldosterone at the mineralocorticoid receptor, 7.5% that of cortisol at the glucocorticoid receptor, and <0.02% that of estradiol at the estrogen receptor.^[2]

Usage

Oral contraceptives

At low doses, levonorgestrel is used in monophasic and triphasic formulations of combined oral contraceptive pills, with available monophasic doses ranging from 100-250 µg, and triphasic doses of 50 µg/75 µg/125 µg.

At very low daily dose of 30 µg, levonorgestrel is used in some progestogen only pill formulations.

Emergency contraception

Levonorgestrel is used in emergency contraceptive pills (ECPs), both in a combined Yuzpe regimen which includes estrogen, and as a levonorgestrel-only method. The levonorgestrel-only method uses levonorgestrel 1500 μg (as a single dose or as two 750 μg doses 12 hours apart) taken within 3 days of unprotected sex. There are many brand names of levonorgestrel-only ECPs, including: Plan B, Levonelle, NorLevo, Postinor-2, and 72-HOURS.^[3]

IUD

Levonorgestrel is the active ingredient in Mirena.

Contraceptive implants

Levonorgestrel is the active ingredient in Norplant and Jadelle.

References

↑ Edgren RA, Stanczyk FZ (1999). "Nomenclature of the gonane progestins". Contraception. 60 (6): 313. PMID 10715364.
↑ Sitruk-Ware R (2006). "New progestagens for contraceptive use". Hum Reprod Update. 12 (2): 169–78. PMID 16291771.
↑ Trussell, James; Cleland, Kelly (2007-04-10). "Emergency Contraceptive Pills Worldwide". Princeton University. Retrieved 2007-05-28.

External links

Levonelle manufacturer's product information from Schering
Monograph for levonorgestrel - Uk Medicines Information

Template:Sex hormones de:Levonorgestrel nl:Levonorgestrel

Template:WikiDoc Sources

[1] Edgren RA, Stanczyk FZ (1999). "Nomenclature of the gonane progestins". Contraception. 60 (6): 313. PMID 10715364.

[2] Sitruk-Ware R (2006). "New progestagens for contraceptive use". Hum Reprod Update. 12 (2): 169–78. PMID 16291771.

[ecp_worldwide-3] Trussell, James; Cleland, Kelly (2007-04-10). "Emergency Contraceptive Pills Worldwide". Princeton University. Retrieved 2007-05-28.

[1]

[2]

[3]

@@ Line 5: / Line 5: @@
 |drugClass=emergency [[contraceptive]]
 |indicationType=prophylaxis
-|indication=pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse.
+|indication=pregnancy following unprotected intercourse or a known or suspected contraceptive failure. To obtain optimal efficacy, the tablet should be taken as soon as possible within 72 hours of intercourse
-|adverseReactions=[[menstrual bleeding]], [[nausea]], [[lower abdominal pain]], [[fatigue]], [[headache]], and [[dizziness]].
+|adverseReactions=[[menstrual bleeding]], [[nausea]], [[lower abdominal pain]], [[fatigue]], [[headache]], and [[dizziness]]
 |blackBoxWarningTitle=<b><span style="color:#FF0000;">TITLE</span></b>
 |blackBoxWarningBody=<i><span style="color:#FF0000;">Condition Name:</span></i> (Content)
@@ Line 92: / Line 92: @@
 |useInRenalImpair=No formal studies were conducted to evaluate the effect of renal disease on the disposition of levonorgestrel tablet.
 |useInHepaticImpair=No formal studies were conducted to evaluate the effect of hepatic disease on the disposition of levonorgestrel tablet.
+|overdose=There are no data on overdosage of levonorgestrel tablet, although the common adverse event of nausea and associated vomiting may be anticipated.
+|drugBox={{Drugbox2
+| Watchedfields = changed
+| verifiedrevid = 462091161
+| IUPAC_name = (8R,9S,10R,13S,14S,17R)-13-ethyl-17-ethynyl-17-hydroxy-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydrocyclopenta[''a'']phenanthren-3-one
+| image = Levonorgestrel.svg
+| width = 220px
+| image2 = Levonorgestrel3D.png
+| width2 = 220px
+<!--Clinical data-->
+| tradename = Norplant
+| Drugs.com = {{drugs.com|monograph|progestins-etonogestrel-levonorgestrel-norethindrone}}
+| MedlinePlus = a610021
+| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
+| pregnancy_US = <!-- A / B / C / D / X -->
+| pregnancy_category = X
+| legal_AU = <!-- Unscheduled / S2 / S4 / S8 -->
+| legal_UK = <!-- GSL / P / POM / CD -->
+| legal_US = <!-- OTC / Rx-only -->
+| legal_status =  Rx-OTC
+| routes_of_administration = [[Implant (medicine)|Implant]]; insert (extended-release); oral
+<!--Pharmacokinetic data-->
+| bioavailability = ~100%
+| protein_bound = 55%
+| metabolism = [[Liver|Hepatic]] via [[CYP3A4]]{{Citation needed|date=April 2014}}
+| elimination_half-life = 36 ± 13 hours
+| excretion = [[Kidney|Renal]]: 45%; [[Feces|Fecal]]:32%
+<!--Identifiers-->
+| CASNo_Ref = {{cascite}}
+| CAS_number_Ref = {{cascite|correct|??}}
+| CAS_number = 797-63-7
+| ATC_prefix = G03
+| ATC_suffix = AC03
+| ATC_supplemental =  {{ATC|G03|AD01}}
+| PubChem = 13109
+| IUPHAR_ligand = 2881
+| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
+ | DrugBank = DB00367
+| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
+| ChemSpiderID = 12560
+| UNII_Ref = {{fdacite|correct|FDA}}
+| UNII = 5W7SIA7YZW
+| KEGG_Ref = {{keggcite|correct|kegg}}
+| KEGG = D00950
+| ChEBI_Ref = {{ebicite|correct|EBI}}
+| ChEBI = 6443
+| ChEMBL_Ref = {{ebicite|correct|EBI}}
+| ChEMBL = 1389
+<!--Chemical data-->
+| C=21 | H=28 | O=2
+| molecular_weight = 312.446 g/mol
+| smiles = [H][C@]12CCC(=O)C=C1CC[C@]1([H])[C@]2([H])CC[C@@]2(CC)[C@@]1([H])CC[C@@]2(O)C#C
+| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChI = 1S/C21H28O2/c1-3-20-11-9-17-16-8-6-15(22)13-14(16)5-7-18(17)19(20)10-12-21(20,23)4-2/h2,13,16-19,23H,3,5-12H2,1H3/t16-,17+,18+,19-,20-,21-/m0/s1
+| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
+| StdInChIKey = WWYNJERNGUHSAO-XUDSTZEESA-N
+}}
+|mechAction=Emergency contraceptive pills are not effective if a woman is already pregnant. Levonorgestrel is believed to act as an emergency contraceptive principally by preventing [[ovulation]] or [[fertilization]] (by altering tubal transport of sperm and/or ova). In addition, it may inhibit [[implantation]] (by altering the [[endometrium]]). It is not effective once the process of [[implantation]] has begun.
+|structure=The inactive ingredients present are colloidal silicon dioxide, corn starch, FD&C Yellow #6, lactose monohydrate,  magnesium stearate, povidone.
+Levonorgestrel has a molecular weight of 312.45, and the following structural and molecular formulas:
+|PK======Absorption=====
+Following a single dose administration of levonorgestrel 1.5 mg in 30 women under fasting conditions, maximum plasma concentrations of levonorgestrel of 19.1 ng/mL were reached at 1.7 hours.
 |alcohol=Alcohol-Levonorgestrel interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.
 }}

Clinical data


Pregnancy category	X
Routes of administration	Implant; insert (extended-release); oral
ATC code	G03AC03 (WHO)
Pharmacokinetic data
Bioavailability	~100%
Protein binding	55%
Metabolism	Hepatic
Elimination half-life	36 ± 13 hours
Excretion	Renal: 45%; Fecal:32%
Identifiers
IUPAC name 13-ethyl-17-ethynyl-17-hydroxy- 1,2,6,7,8,9,10,11,12,13,14,15,16, 17- tetradecahydrocyclopenta[a] phenanthren-3-one
CAS Number	797-63-7
PubChem CID	13109
DrugBank	APRD00754
E number	{{#property:P628}}
ECHA InfoCard	{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
Formula	C₂₁H₂₈O₂
Molar mass	312.446 g/mol

Levonorgestrel (oral): Difference between revisions

Revision as of 15:21, 12 January 2015

Disclaimer

Overview

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Emergency Contraceptive

Menorrhagia

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

Non–Guideline-Supported Use

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

Non–Guideline-Supported Use

Contraindications

Warnings

Ectopic Pregnancy

Existing Pregnancy

Effect on Menses

STI/HIV

Physical Examination and Follow-up

Fertility Following Discontinuation

Presence of FD&C Yellow

Adverse Reactions

Clinical Trials Experience

Postmarketing Experience

Gastrointestinal Disorders

General Disorders and Administration Site Conditions

Nervous System Disorders

Reproductive System and Breast Disorders

Drug Interactions

Use in Specific Populations

Pregnancy

Labor and Delivery

Nursing Mothers

Pediatric Use

Geriatic Use

Gender

Race

Renal Impairment

Hepatic Impairment

Females of Reproductive Potential and Males

Immunocompromised Patients

Administration and Monitoring

Administration

Monitoring

IV Compatibility

Overdosage

Pharmacology

Mechanism of Action

Structure

Pharmacodynamics

Pharmacokinetics

Absorption

Nonclinical Toxicology

Clinical Studies

How Supplied

Storage

Images

Drug Images

Package and Label Display Panel

Patient Counseling Information

Precautions with Alcohol

Brand Names

Look-Alike Drug Names

Drug Shortage Status

Price

References

Chemistry

Usage

Oral contraceptives

Emergency contraception

IUD

Contraceptive implants

References

External links

Navigation menu

Search